Clinical trial

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or…

NCT00359463 · GlaxoSmithKline, Industry · Completed

Key facts

NCT number NCT00359463
Title Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
Official title An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50mg Eltrombopag in Healthy Subjects and in Volunteers With Mild, Moderate or Severe Hepatic Impairment
Lead sponsor GlaxoSmithKline, Industry
Status Completed
Phase Phase 1
Study type Interventional
Conditions Purpura, Thrombocytopaenic, Idiopathic
Intervention type Drug
Interventions eltrombopag
Enrollment 33
Start date Apr 18, 2006
Primary completion Mar 7, 2007
Completion Mar 7, 2007
First posted Aug 2, 2006
Last update posted Nov 13, 2017
Countries Australia, New Zealand, United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies